Skip to main content

Brorphine Facts

Opioid; Depressant; Substituted piperidine; Mu-opioid receptor agonist

Description

Brorphine (3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one) is a synthetic opioid of the piperidine benzimidazolone class. It activates opioid receptors in the brain, suppressing pain signals and slowing the drive to breathe.[1]

Subjective effects include deep pain suppression, euphoria, heavy sedation, warmth, and complete suppression of distress. The experience is defined by what it removes — pain, anxiety, and awareness of the body fade into a quiet, weighted calm.

Brorphine carries high abuse liability, and standard naloxone doses may not fully reverse its respiratory depression.[2] Every documented death involved fentanyl and benzodiazepines — brorphine has not been found in illicit supply as a standalone drug.[3]

Dose and durationby route · individual sensitivity varies

Insufflated(mg)
Threshold< 0.5 mgLight1 – 2 mgCommon2 – 5 mgStrong5 – 8 mgHeavy10+ mg

Starts in 5 – 15 minLasts 4 – 8 hoursAfter-effects 4 – 12 hours

Body and dependence

Acute toxicity
Critical
Chronic toxicity
High
Physical dependence
High
Psychological dependence
High
Withdrawal
Severe · medical supervision
Compulsive redosing
High

Tolerance

Builds
Rapid
Fully resets after
14 days
Carries over to
morphine; fentanyl; hydromorphone; methadone; heroin; oxycodone

Effectslikely at a common dose

Perception
Dreaming suppression; Sleep-transition hallucinations; +5 possible, including Spatial disorientation, Vestibular distortion, Visual acuity suppression
Body
Muscle relaxation; Bodily heaviness; Body high; Breathing alteration; Constipation; Pain suppression; Pupil constriction; Respiratory depression; +17 possible, including Dizziness, Motor control impairment, Nausea
Thinking
Cognitive fatigue; Cognitive impairment; Focus suppression; Information processing suppression; Thought deceleration; +12 possible, including Analysis suppression, Compulsive redosing urge, Decision impairment
Feeling
Euphoria; +2 possible
Self
none likely · 6 possible, including Craving, Communication suppression, Social disconnection
Time
none likely · 2 possible, including Temporal disorientation

Who shouldn't take it

Absolute
Respiratory insufficiency; Pregnancy; Concurrent CNS depressant use
Relative
Head injury or elevated intracranial pressure; Severe hepatic dysfunction; MAOI co-administration

Combinations60 recorded

Lethal (4)
Benzodiazepines, Barbiturates; GHB, Baclofen; GHB, GBL; Local anesthetics
Dangerous (28)
Alpha-2 adrenergic receptor antagonist; Amphetamines; Anticholinergics; Antihistamines; Antipsychotics; Benzodiazepines; Buprenorphine, Kratom; Cannabis, THC; Clonidine, Guanfacine; Gabapentin, Pregabalin; MAOIs; MDMA, Amphetamines; MDMA, MDA; Naltrexone; NRIs; SNRIs; SSRIs; Stimulants; Synthetic cannabinoids; THC; Caffeine; CBD; Glutamate modulator; Huperzine A; and 4 more, see full page
Caution (19)
See full page: psychedex.org/substances/brorphine
Not graded (9)
Not listed never means safe.

Seek help immediately if

  • Unresponsive / can't be woken, even to a firm sternal rub
  • Slow, shallow, or stopped breathing
  • Pinpoint pupils
  • Blue/grey lips, fingertips, or skin (cyanosis)
  • Limp body; pale, clammy skin
  • Choking or gurgling sounds ("death rattle")
  • Slow, erratic, or absent pulse

What to do

  1. Try to wake them — shout their name, firm sternal rub
  2. Call emergency services immediately
  3. Administer naloxone if available
  4. Give rescue breaths (or CPR if there is no pulse)
  5. Place them in the recovery position
  6. Stay with them; re-dose naloxone every 2–3 minutes if there is no response
Reversal agent
Naloxone (Narcan) — opioid antagonist. May require repeated doses; its effect can wear off before the opioid does.

With prompt naloxone and rescue breathing, reversal is usually rapid. Because naloxone can wear off before the opioid — especially with long-acting opioids (methadone) or high-potency ones (fentanyl) — a period of monitoring is needed even after the person revives.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Vandeputte MM, Cannaert A, Stove CP (2020) In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances — Archives of Toxicology doi:10.1007/s00204-020-02855-7
  2. [2]
    ^Vandeputte MM, Bilel S, Tirri M, Corli G, Bassi M, Layle NK, Fantinati A, Walther D, Iula DM, Baumann MH, Stove CP, Marti M (2024) Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization — Neuropharmacology doi:10.1016/j.neuropharm.2024.110113
  3. [3]
    ^Krotulski AJ, Papsun DM, Noble C, Kacinko SL, Logan BK (2021) Brorphine-Investigation and quantitation of a new potent synthetic opioid in forensic toxicology casework using liquid chromatography-mass spectrometry — Journal of Forensic Sciences doi:10.1111/1556-4029.14623
Print version
Report an issue